Drugs / Formulation B
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06790290 | Jan → Apr 2025 overdue | pneumococcal infection | Inventprise Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03572062 | Jun 2018 → Jun 2020 | respiratory tract infectious disorder | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Formulation B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03572062 ↗ |
| Modality | Vaccine | “a 25 valent conjugated pneumococcal vaccine with adjuvant” NCT06790290 ↗ |
| Route | Intramuscular | “administered by intramuscular injection” NCT06790290 ↗ |